Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 3, 2018

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Breast Neoplasms
Interventions
DRUG

Formal study using hyperpolarized 13C-pyruvate injection

Administration at two visits 1) after completion of cardiotoxic therapy and 2) 1 to 6 months after the first time point following medical therapy (SOC)

DRUG

Feasible study using hyperpolarized 13C-pyruvate injection

Administration at two visits: 1) baseline MRI before administration of cardiotoxic therapy and 2) after completion of cardiotoxic therapy

Trial Locations (1)

75390

UT Southwestern - Advanced Imaging Research Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT03685175 - Using Hyperpolarized [1-13C]Pyruvate to Detect Cardiotoxicity | Biotech Hunter | Biotech Hunter